Innovations In Clinical Neuroscience

MAR-APR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 53 of 55

54 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE March–April 2018 • Volume 15 • Number 3–4 AUTHOR GUIDELINES VOL. 15, NO. 3–4 • MARCH–APRIL 2018 INNOVATIONSCNS.COM Submission requirements for Innovations in Clinical Neuroscience (Online ISSN 2158-8341, Print ISSN 2158-8333) are in accordance with the International Committee of Medical Journal Editors (ICMJE). See Uniform Requirements for Manuscripts Submitted to Biomedical Journals. EDITORIAL PURPOSE Innovations in Clinical Neuroscience is a peer-reviewed electronic-only journal ( designed to provide healthcare clinicians and researchers with up-to-date, evidence-based information in a straightforward "how-to" fashion on new or emerging treatment options, drug development trends, theoretical concepts, drug trial methodology, and practice management issues in the field of neuroscience, including psychiatry, neurology, pain, and Alzheimer's, to improve patient outcomes. SCOPE OF MANUSCRIPTS Manuscripts that meet our editorial purpose include but are not limited to: (1) reports of preclinical and clinical research studies that expand existing knowledge in the field of neuroscience; (2) case reports, case series, and case studies that stimulate research and the exchange of information beyond what is currently found in the literature in the field of neuroscience; (3) in-depth reviews that synthesize new or emerging information on treatment options, drug development, drug trial methodology, practice management, reimbursement, education, ethics, and legal issues in the field of neuroscience; (4) reports on contemporary issues in neuroscience that may affect drug or device development, delivery of services, reimbursement, and clinical practice of psychiatry, neurology, or related fields; and (5) commentaries that offer unique, substantiated discussions on theorectical concepts, current or emerging trends in clinical practice (including treatment and diagnosis issues), trial methodology, drug development, regulatory issues, or other topics related to neuroscience that affect patient outcome. Original Research. Reports of investigations that address questions about clinical care or clinical trial methodology or expand existing knowledge. References and abstract are required. Illustrative material is recommended. Recommended length: up to 6000 words, not including references. Review Articles. Comprehensive articles that synthesize and summarize the latest research to facilitate the clinician's approach to diagnosis and treatment and articles highlighting emerging diagnostic and therapeutic modalities. May also include in-depth reviews of clinical practice, pracice management, drug development, trial methodology, reimbursement and educational, ethical, or legal issues. References (at least 25 current references are recommended) and abstract required. Illustrative material is preferred. Recommended length: up to 6000 words, not including references. Case Series, Studies, or Reports. Short presentations of actual cases that stimulate research and the exchange of information beyond what is currently found in the literature and illustrate the signs and symptoms, diagnosis, and treatment of a disorder. Case presentations should provide unique or new information that is not well-covered in the current literature. References (at least 15 current references are recommended) and abstract required. Illustrative material is preferred. Recommended length 1000 to 3000 words, not including references. Brief Reports. Short reports of original studies, trial methodology, or case series. Must include abstract. Recommended length: 1000 to 1500 words (not including references). Commentaries. Essays that address important topics in neuroscience and generally are not linked to a specific article. Commentaries should offer unique perspectives that are well focused, scholarly, and clearly presented. Include approximately 20 references. Recommended length: 1500 to 2000 words. Letters to the Editor. Opinions on cases or articles published in Innovations in Clinical Neuroscience, opinions on other current topics, or short reports of clinical interest. Must be concise and to the point. Text should not exceed 600 words (not including references), with no more than 10 references. Letters regarding a specific article published in Innovations in Clinical Neuroscience should be received within four months of the article's publication release and may be sent to the original author for reply. Submission of a letter does not guarantee publication or response. Notify editor if letter is not intended for publication should be The editor reserves the right to edit the material for style, clarity, and size. MANUSCRIPT SUBMISSION Submissions for consideration may be submitted online via Editorial Manager available at icns/default.aspx. Emailed submissions no longer accepted. Corresponding Author. Each manuscript submission should have a designated corresponding author. The corresponding author will be the editor's single point of contact and will be responsible for communicating any information from the editor regarding the submitted manuscript to the coauthors. Cover Letter. Manuscripts should be submitted with a cover letter indicating the article type. The cover letter should give details on any previous or duplicate publication of any of the content and should state that the paper is not under consideration for publication elsewhere. In the cover letter, authors should disclose any potential financial conflicts of interest relevant to the submitted manuscript. For Letters to the Editor, please indicate whether the letter is intended for publication. Conflict of Interest Disclosures. All authors should disclose any potential financial conflicts of interest relevant to the submitted manuscript in the cover letter of the submitted manuscript. Author and Copyright Forms. Upon submission, corresponding author will receive an acknowledgement email with author and copyright forms attached. It is the responsibility of the corresponding author to distribute the author and copyright forms to all of the coauthors. All authors for each submission are required to complete, sign, and return these forms prior to publication. The corresponding author may not sign on behalf of any coauthor.If the manuscript is accepted and published in Innovations in Clinical Neuroscience, authors must transfer copyright to Matrix Medical Communications. Registration of Clinical Trials. As recommended by the ICMJE, Innovations in Clinical Neuroscience requires as a condition of consideration for publication registration of all clinical trials in a public trials registry that requires the minimum registration data set as determined by the ICMJE, which can be accessed via http://www. Please include the trial registry name, registration number, and the url for the registry in the abstract. Protection of Research Participants. When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate. Patient Consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication. Patient consent should be written and archived with the authors. The authors must provide the journal with a written statement that attests that they have received and archived written patient consent. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, authors should provide assurance, and editors should so note, that such changes do not distort scientific meaning. Animal experiments. Manuscripts will be considered for publication only if the work follows international, national, and/or institutional guidelines for humane animal treatment and complies with relevant legislation; has been approved by the ethics review committee at the institution or practice at which the studies were conducted where such a committee exists; and for studies using client-owned animals, demonstrates a high standard (best practice) of veterinary care and involves informed client consent. Prior to acceptance of a manuscript, to verify compliance with the above policies, the authors must include a signed statement that legal and ethical requirements were met with regard to the humane treatment of animals described in the study. Author must also describe in Materials and Methods section(s) of the manuscript the ethical review committee approval process and the international, national, and/or institutional guidelines that were followed. Inclusion of Previously Published Materials. Any material submitted to Innovations in Clinical Neuroscience that is reproduced from previously published copyrighted material must be accompanied by a letter of permission from the copyright holder UPON SUBMISSION. All such material should include a full credit line (e.g., in the figure or table legend) acknowledging the original source. The author is responsible for obtaining the permission and is responsible for any associated fees. MANUSCRIPT PREPARATION Title Page. The title page should contain the following elements: title, author names and institutional affiliations, sources of financial support, name of corresponding author with his or her complete contact information (mailing address, telephone and fax numbers, e-mail address), and word count (text only). Spacing and Pagination. The manuscript should be typed using double spacing throughout. Do not use a running head. Pages

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAR-APR 2018